metricas
covid
Annals of Hepatology Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genot...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance
Deanna D. Hilla,
Corresponding author
deanna.hill@merck.com

Corresponding author.
, Jennifer R. Kramerb,c, Kassie R. Chaffinb, T. Christopher Masta, Michael N. Robertsona, Fasiha Kanwalb,c, Barbara A. Habera
a Merck & Co., Inc., Rahway, NJ, United States
b Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX, United States
c Department of Medicine, Baylor College of Medicine, Houston, TX, United States
Read
1783
Times
was read the article
209
Total PDF
1574
Total HTML
Share statistics
Article information
ISSN: 16652681
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 12 34 12 46
2025 11 207 28 235
2025 10 121 10 131
2025 9 85 21 106
2025 8 73 9 82
2025 7 139 11 150
2025 6 75 3 78
2025 5 62 5 67
2025 4 53 2 55
2025 3 69 5 74
2025 2 41 4 45
2025 1 30 0 30
2024 12 25 2 27
2024 11 36 6 42
2024 10 23 2 25
2024 9 31 0 31
2024 8 21 5 26
2024 7 23 3 26
2024 6 29 1 30
2024 5 25 2 27
2024 4 18 9 27
2024 3 30 6 36
2024 2 36 10 46
2024 1 39 1 40
2023 12 17 4 21
2023 11 15 3 18
2023 10 23 5 28
2023 9 13 3 16
2023 8 11 1 12
2023 7 10 1 11
2023 6 27 3 30
2023 5 50 1 51
2023 4 45 4 49
2023 3 33 10 43
2023 2 5 10 15
2023 1 0 7 7
Show all

Follow this link to access the full text of the article